Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple-Threat vaccine aims to shield seniors from three respiratory viruses

NCT ID NCT06984094

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Clover Biopharmaceuticals AUS Pty Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two new vaccines (SCB-1022 and SCB-1033) designed to protect against RSV, human metapneumovirus, and parainfluenza virus. About 612 healthy adults aged 60-85 will receive either a vaccine or a placebo. The main goal is to check safety and how well the vaccines trigger an immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
combination recombinant protein subunit vaccines (SCB-1022 and SCB-1033)
What this could lead to
If successful, these vaccines could protect older adults against three common respiratory viruses (RSV, hMPV, and PIV3) with a single shot.
What could go wrong
This is an early first-in-human study, so safety and immune response are still being tested. The vaccines may not work as hoped or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN METAPNEUMOVIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Paramyxoviridae infectious disease parainfluenza infectious disease prevention target respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUMAN METAPNEUMOVIRUS INFECTION PARAINFLUENZA INFECTION RSV INFECTION

Contacts and locations

Locations

  • Fusion Clinical Research

    Adelaide, Southern Australia, 5067, Australia

  • Linear Clinical Research

    Perth, Western Australia, 6009, Australia

  • Paratus Clinical Research

    Melbourne, Victoria, 3070, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.